- RecruitingPHASE1, PHASE2
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
This study is testing a new medicine, STP938, for adults with specific types of lymphoma (blood cancer) that have come back after previous treatments. It aims to find a safe dose and see how well it works in different kinds of B-cell and T-cell lymphomas.
For: Lymphoma, B-Cell · Lymphoma, T-CellUnited States · France · United Kingdom - RecruitingPHASE1
Study of STP938 in Advanced Solid Tumours
This study is testing a new drug called STP938 for people with advanced solid tumours that haven't responded to other treatments. It aims to find the right dose and check how safe the drug is when given alone.
For: Solid TumorUnited States · France · United Kingdom - RecruitingPHASE1
A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia
This study looks at a new drug, STP938, for essential thrombocythaemia (ET) in adults where current treatment isn't working. It aims to see if STP938 safely lowers high platelet counts. Participants take the drug daily for up to a year, with regular check-ups.
For: Essential ThrombocythaemiaFrance · United Kingdom